# Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

> **NCT05358080** · PHASE4 · UNKNOWN · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 396 (estimated)

## Conditions studied

- Non Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Entelon Tab. 50mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05358080
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-27
- **Primary completion:** 2024-12-16
- **Final completion:** 2024-12-16
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358080, "Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05358080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*